Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison

Autores de IIS La Fe

• Adela Cañete Nieto

  Autor

Participantes ajenos a IIS La Fe

• Lode H.N.
• Holko P.
• Wieczorek A.
• Siebert N.
• Valteau-Couanet D.
• Garaventa A.
• Anderson J.
• Yaniv I.
• Ash S.
• Gray J.
• Luksch R.
• Manzitti C.
• Troschke-Meurer S.
• Ebeling T.
• Kawalec P.
• Sladowska K.
• Ladenstein R.L.

Grupos

• Investigación Clínica y Traslacional en Cáncer

Abstract

Abstract no disponible

Keywords

• dinutuximab; naxitamab; Article; cancer survival; computer assisted tomography; data quality assessment; drug efficacy; drug safety; event free survival; human; neuroblastoma; nuclear magnetic resonance imaging; overall response rate; overall survival; phase 2 clinical trial (topic); progression free survival; randomized controlled trial (topic); stem cell transplantation; systematic review; treatment response